Simple blood test could open lifesaving cancer drug to more patients
NCT ID NCT06129084
Summary
This study is testing whether a blood test can more accurately identify patients with advanced bladder cancer who are eligible for a targeted drug called erdafitinib. Currently, doctors use a tissue sample from a past biopsy, which may not reflect the current state of the cancer. Researchers will compare the blood test results to the standard tissue test in 260 patients to see if the blood test finds more people who could benefit from the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arthur J.E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
BC Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
-
CHU de Québec-Université Laval
Québec, Quebec, G1R 2J6, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.